114 results
10-K/A
2022 FY
ATNXQ
Athenex, Inc.
28 Apr 23
Annual report (amended)
8:10am
of the Scientific Advisory Counsel for Mallinckrodt Pharmaceuticals, member of the Hepatology Counsel for Novartis, and Chairman of the Data Safety and Management … of the Data Monitoring and Safety Board and Protocol Review Board for the Clinical Trial Network of the National Institute on Drug Abuse of the U.S. National
8-K
EX-99.1
ATNXQ
Athenex, Inc.
3 Nov 22
Athenex Provides Third Quarter 2022 Financial Results and Business Update
7:10am
innovative, first-in-class NKT cell therapy platform with potential for improved efficacy, safety, and accessibility over current cell therapy approaches … :
Phase 1 GINAKIT2 study dose escalation, safety, and preliminary efficacy data update in 1H 2023
KUR-502:
Next clinical trial data update from
DEFA14A
ATNXQ
Athenex, Inc.
11 Oct 22
Additional proxy soliciting materials
8:31am
candidates; the Company’s ability to successfully demonstrate the safety and efficacy of its drug candidates and gain approval of its drug candidates
8-K
jr3 5hx7yv
3 Oct 22
Entry into a Material Definitive Agreement
4:16pm
8-K
EX-10.1
be2bwhojwbw65ota
15 Aug 22
Athenex, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Warrants
12:00am
424B5
2j3o nuled
12 Aug 22
Prospectus supplement for primary offering
3:55pm
424B5
qzdnjuuz90n4y
10 Aug 22
Prospectus supplement for primary offering
5:18pm
8-K
EX-99.1
yjtsaxb
28 Jul 22
Athenex Provides Second Quarter 2022 Financial Results and Business Update
7:05am
8-K
EX-99.1
gu0k4oeiirg1yq5s6e7
11 Jul 22
Expected sale proceeds of approximately $19.0 million
4:15pm
8-K
jl3xl1 l6x0j4p61evos
11 Jul 22
Expected sale proceeds of approximately $19.0 million
4:15pm
8-K
EX-99.1
sepoz7 qx90aur9
24 Jun 22
Company executes on strategy to extend cash runway by monetizing non-core assets
4:31pm
8-K
qybelxlz7n83
24 Jun 22
Company executes on strategy to extend cash runway by monetizing non-core assets
4:31pm